利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

112 条记录 (耗时 0.042 秒)

    Anti human ovarian cancer-anti CD3 bispecific antibody
    12.
    发明授权
    Anti human ovarian cancer-anti CD3 bispecific antibody 失效
    抗人卵巢癌抗CD3双特异性抗体

    公开(公告)号：US07262276B2

    公开(公告)日：2007-08-28

    申请号：US10478345

    申请日：2002-05-23

    申请人： Hualiang Huang ,  Xin Jiang ,  Min Fang ,  Xiaocong Yu ,  Jie Feng ,  Ping Zhou ,  Qing Lin

    发明人： Hualiang Huang ,  Xin Jiang ,  Min Fang ,  Xiaocong Yu ,  Jie Feng ,  Ping Zhou ,  Qing Lin

    IPC分类号： C07K16/30

    CPC分类号： C07K16/2809 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622

    摘要： The present invention provides an anti-ovarian cancer bispecific antibody. Said antibody includes two polypeptide domains connected by a polypeptide linker, one is anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody or single chain Fv (scFv) and the other is anti-CD3 antibody, or its Fab fragment, single CDR antibody or scFv. The present invention also provides DNA sequences encoding said antibody, an expression vector containing said DNA sequence, and a host cell containing said expression vector.

    摘要翻译： 本发明提供了抗卵巢癌双特异性抗体。 所述抗体包括通过多肽接头连接的两个多肽结构域，一个是抗卵巢癌抗体或其Fab片段，单互补决定区（CDR）抗体或单链Fv（scFv），另一个是抗CD3抗体，或 其Fab片段，单CDR抗体或scFv。 本发明还提供编码所述抗体的DNA序列，含有所述DNA序列的表达载体和含有所述表达载体的宿主细胞。

    MOBILE TERMINAL AND A METHOD FOR IMPLEMENTING THE GUARDIANSHIP FUNCTION
    13.
    发明申请
    MOBILE TERMINAL AND A METHOD FOR IMPLEMENTING THE GUARDIANSHIP FUNCTION 有权
    移动终端和实现监护功能的方法

    公开(公告)号：US20070197193A1

    公开(公告)日：2007-08-23

    申请号：US11692732

    申请日：2007-03-28

    申请人： Ping Zhou

    发明人： Ping Zhou

    IPC分类号： H04M1/66

    CPC分类号： H04M1/72552 ,  H04M1/72538 ,  H04M1/72544 ,  H04W4/14

    摘要： A mobile terminal with a guardianship function, includes: a first module, configured for collecting data related to use of the mobile terminal; a second module, configured for determining the use of the mobile terminal by analyzing the data collected by the first module; and a third module, configured for sending a short message informing the use of the mobile terminal determined by the second module. A method for performing the guardianship function at a mobile terminal is also provided. By using the mobile terminal and the method, a guardian is able to timely learn a ward's use of the mobile terminal, thus effectively monitoring the ward.

    摘要翻译： 一种具有监护功能的移动终端，包括：第一模块，用于收集与所述移动终端的使用有关的数据; 第二模块，被配置为通过分析由所述第一模块收集的数据来确定所述移动终端的使用; 以及第三模块，被配置为发送通知由所述第二模块确定的所述移动终端的使用的短消息。 还提供了一种用于在移动终端执行监护功能的方法。 通过使用移动终端和方法，监护人能够及时了解病房对移动终端的使用情况，从而有效监控病房。

    Mono- and diacylglycerol acyltransferases and methods of use thereof
    14.
    发明授权
    Mono- and diacylglycerol acyltransferases and methods of use thereof 失效
    单和二酰基甘油酰基转移酶及其使用方法

    公开(公告)号：US07045326B2

    公开(公告)日：2006-05-16

    申请号：US10046924

    申请日：2002-01-14

    申请人： Sylvaine Cases ,  Scot J. Stone ,  Ping Zhou ,  Robert V. Farese, Jr. ,  Chi-Liang Eric Yen

    发明人： Sylvaine Cases ,  Scot J. Stone ,  Ping Zhou ,  Robert V. Farese, Jr. ,  Chi-Liang Eric Yen

    IPC分类号： C12N9/10 ,  C07H21/04

    CPC分类号： C12N9/1029 ,  A01K2217/05 ,  A61K38/00 ,  A61K2039/505 ,  C12Y203/0102 ,  C12Y203/01022

    摘要： Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase and/or monoacylglycerol acyltransferase activity, as well as the polypeptide products encoded thereby, i.e., mammalian DGAT2α and MGAT1 polypeptide products, and methods for producing the same, are provided. Also provided are: methods and compositions for modulating DGAT2α and MGAT1 activity; DGAT2α and MGAT1 transgenic cells, animals and plants, as well as methods for their preparation; and methods for making diglyceride, diglyceride compositions, triglycerides and triglyceride compositions, as well as the compositions produced by these methods. The subject methods and compositions find use in a variety of different applications, including research, medicine, agriculture and industry applications.

    摘要翻译： 提供了编码具有甘油二酯酰基转移酶和/或单酰基甘油酰基转移酶活性的多肽产物的核酸组合物，以及由此编码的多肽产物，即哺乳动物DGAT2α和MGAT1多肽产物及其制备方法。 还提供了：用于调节DGAT2alpha和MGAT1活性的方法和组合物; DGAT2alpha和MGAT1转基因细胞，动物和植物，以及它们的制备方法; 以及制备甘油二酯，甘油二酯组合物，甘油三酯和甘油三酯组合物的方法以及通过这些方法制备的组合物。 主题方法和组合物可用于各种不同的应用，包括研究，医学，农业和工业应用。

    Mono-and diacylglycerol acyltransferases and methods of use thereof
    16.
    发明申请
    Mono-and diacylglycerol acyltransferases and methods of use thereof 审中-公开
    单酰基甘油和二酰基甘油酰基转移酶及其使用方法

    公开(公告)号：US20050106697A1

    公开(公告)日：2005-05-19

    申请号：US10945738

    申请日：2004-09-20

    申请人： Sylvaine Cases ,  Scot Stone ,  Ping Zhou ,  Robert Farese ,  Chi-Liang Yen

    发明人： Sylvaine Cases ,  Scot Stone ,  Ping Zhou ,  Robert Farese ,  Chi-Liang Yen

    IPC分类号： A61K38/00 ,  C12N9/10 ,  C07H21/04 ,  C12P7/64

    CPC分类号： C12N9/1029 ,  A01K2217/05 ,  A61K38/00 ,  A61K2039/505 ,  C12Y203/0102 ,  C12Y203/01022

    摘要： Nucleic acid compositions encoding polypeptide products with diglyceride acyltransferase and/or monoacylglycerol acyltransferase activity, as well as the polypeptide products encoded thereby, i.e., mammalian DGAT2α, MGAT1, or MGAT2 polypeptide products, and methods for producing the same, are provided. Also provided are: methods and compositions for modulating DGAT2α, MGAT1, or MGAT2 activity; DGAT2α, MGAT1, or MGAT2 transgenic cells, animals and plants, as well as methods for their preparation; and methods for making diglyceride, diglyceride compositions, triglycerides and triglyceride compositions, as well as the compositions produced by these methods. The subject methods and compositions find use in a variety of different applications, including research, medicine, agriculture and industry applications.

    摘要翻译： 提供了编码具有甘油二酯酰基转移酶和/或单酰基甘油酰基转移酶活性的多肽产物的核酸组合物，以及由此编码的多肽产物，即哺乳动物DGAT2α，MGAT1或MGAT2多肽产物及其制备方法。 还提供了：用于调节DGAT2α，MGAT1或MGAT2活性的方法和组合物; DGAT2α，MGAT1或MGAT2转基因细胞，动物和植物，以及它们的制备方法; 以及制备甘油二酯，甘油二酯组合物，甘油三酯和甘油三酯组合物的方法以及通过这些方法制备的组合物。 主题方法和组合物可用于各种不同的应用，包括研究，医学，农业和工业应用。

    N-aryloxyethylamine derivatives for the treatment of depression
    18.
    发明授权
    N-aryloxyethylamine derivatives for the treatment of depression 失效
    N-芳氧基乙胺衍生物用于治疗抑郁症

    公开(公告)号：US6110956A

    公开(公告)日：2000-08-29

    申请号：US287416

    申请日：1999-04-07

    申请人： Richard E. Mewshaw ,  Dahui Zhou ,  Ping Zhou

    发明人： Richard E. Mewshaw ,  Dahui Zhou ,  Ping Zhou

    IPC分类号： A61P25/24 ,  C07D209/14 ,  C07D403/12 ,  C07D405/12 ,  A61K31/404 ,  A61K31/4045 ,  C07D209/04 ,  C07D403/08

    CPC分类号： C07D403/12 ,  C07D209/14 ,  C07D405/12

    摘要： Compounds effective in treating disorders of the serotonin-affected neurological systems are provided, such compounds having the following formula: ##STR1## wherein: R.sub.1 and R.sub.2 are each, independently, hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, MeSO.sub.2, or together can form a 5-7 membered carbocyclic or heterocyclic ring;R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl;R.sub.4 is hydrogen, hydroxy, lower alkyl, or lower alkoxy;R.sub.5 is hydrogen, lower alkyl, or halogen;R.sub.6 is hydrogen, lower alkyl, or phenyl;R.sub.7 is hydrogen, lower alkyl, lower alkoxy, halogen, CN, CF.sub.3, or hydroxy; andX is (CH.sub.2).sub.n,wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.

    摘要翻译： 提供了有效治疗受5-羟色胺影响的神经系统疾病的化合物，具有下式的化合物：其中：R 1和R 2各自独立地为氢，卤素，CF 3，低级烷基，低级烷氧基，MeSO 2或一起可形成 5-7元碳环或杂环; R3是烷氧基，卤素，氢或氨基甲酰基; R4是氢，羟基，低级烷基或低级烷氧基; R5是氢，低级烷基或卤素; R6是氢，低级烷基或苯基; R7是氢，低级烷基，低级烷氧基，卤素，CN，CF3或羟基; X为（CH 2）n，n为0〜3; 或其药学上可接受的盐。

    Process for pyrimidinone compounds
    19.
    发明授权
    Process for pyrimidinone compounds 失效
    嘧啶酮化合物的方法

    公开(公告)号：US6054582A

    公开(公告)日：2000-04-25

    申请号：US207547

    申请日：1998-12-08

    申请人： Ping Zhou ,  Edward Curtis Taylor ,  Colin Michael Tice

    发明人： Ping Zhou ,  Edward Curtis Taylor ,  Colin Michael Tice

    IPC分类号： B01J31/24 ,  C07B61/00 ,  C07D239/36 ,  C07D239/52 ,  C07D239/60 ,  C07D401/04 ,  C07F7/08 ,  C07D239/54

    CPC分类号： C07D239/36 ,  C07D239/52 ,  C07D239/60 ,  C07D401/04 ,  C07F7/0812 ,  C07F7/0827 ,  C07F7/083

    摘要： This invention relates to a process for the preparation of pyrimidinone compounds of the formula ##STR1## wherein Ar is an optionally substituted aryl or heteroaromatic moiety,R.sup.3 is an optionally substituted alkyl, alkenyl or alkynyl,R.sup.5 is a hydrogen atom, halo, cyano or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy or alkylthio, andR.sup.6 is a hydrogen atom, cyano, or an optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl. The process comprises reaction of an amidine and a malonic acid derivative to give a hydroxypyrimidinone followed by conversion of the resulting hydroxypyrimidinone to a sulfonyloxypyrimidinone followed by reaction of the resulting sulfonyloxypyrimidinone with an organometallic reagent to give the desired pyrimidinone. The hydroxypyrimidinones, wherein R.sup.6 is hydroxy and sulfonyloxypyrimidinones wherein R.sup.6 is a substituted sulfonyloxy moiety, are themselves new and useful intermediates in the preparation of the desired pyrimidinones.

    摘要翻译： 本发明涉及一种制备下式的嘧啶酮化合物的方法，其中Ar是任选取代的芳基或杂芳族部分，R 3是任选取代的烷基，烯基或炔基，R 5是氢原子，卤素，氰基或任选取代的 烷基，烯基，炔基，烷氧基或烷硫基，R6是氢原子，氰基或任意取代的烷基，环烷基，烯基，炔基，芳基，芳烷基或杂芳基。 该方法包括脒和丙二酸衍生物的反应，得到羟基嘧啶酮，随后将所得羟基嘧啶酮转化为磺酰氧基嘧啶酮，随后将所得的磺酰氧基嘧啶酮与有机金属试剂反应，得到所需的嘧啶酮。 其中R6是羟基的羟基嘧啶酮和其中R6是取代的磺酰氧基部分的磺酰氧基嘧啶酮本身是制备所需嘧啶酮的新的和有用的中间体。

    Process for pyrimidinone compounds
    20.
    发明授权
    Process for pyrimidinone compounds 失效

    公开(公告)号：US6051710A

    公开(公告)日：2000-04-18

    申请号：US207892

    申请日：1998-12-08

    申请人： Ping Zhou ,  Edward Curtis Taylor ,  Colin Michael Tice

    发明人： Ping Zhou ,  Edward Curtis Taylor ,  Colin Michael Tice

    IPC分类号： B01J31/24 ,  C07B61/00 ,  C07D239/36 ,  C07D239/52 ,  C07D239/60 ,  C07D401/04 ,  C07F7/08

    CPC分类号： C07D239/36 ,  C07D239/52 ,  C07D239/60 ,  C07D401/04 ,  C07F7/0812 ,  C07F7/0827 ,  C07F7/083

    摘要： This invention relates to a process for the preparation of pyrimidinone compounds of the formula ##STR1## wherein Ar is an optionally substituted aryl or heteroaromatic moiety,R.sup.3 is an optionally substituted alkyl, alkenyl or alkynyl,R.sup.5 is a hydrogen atom, halo, cyano or an optionally substituted alkyl, alkenyl, alkynyl, alkoxy or alkylthio, andR.sup.6 is a hydrogen atom, cyano, or an optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl.The process comprises reaction of an amidine and a malonic acid derivative to give a hydroxypyrimidinone followed by conversion of the resulting hydroxypyrimidinone to a sulfonyloxypyrimidinone followed by reaction of the resulting sulfonyloxypyrimidinone with an organometallic reagent to give the desired pyrimidinone. The hydroxypyrimidinones, wherein R.sup.6 is hydroxy and sulfonyloxypyrimidinones wherein R.sup.6 is a substituted sulfonyloxy moiety, are themselves new and useful intermediates in the preparation of the desired pyrimidinones.